EP1223961A4 - "trail" en tant qu'inhibiteur de l'inflammation auto-immune et de la progression du cycle cellulaire - Google Patents

"trail" en tant qu'inhibiteur de l'inflammation auto-immune et de la progression du cycle cellulaire

Info

Publication number
EP1223961A4
EP1223961A4 EP00967122A EP00967122A EP1223961A4 EP 1223961 A4 EP1223961 A4 EP 1223961A4 EP 00967122 A EP00967122 A EP 00967122A EP 00967122 A EP00967122 A EP 00967122A EP 1223961 A4 EP1223961 A4 EP 1223961A4
Authority
EP
European Patent Office
Prior art keywords
trail
autoimmune
ignition
inhibitor
cell cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00967122A
Other languages
German (de)
English (en)
Other versions
EP1223961A1 (fr
Inventor
Youhai Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Publication of EP1223961A1 publication Critical patent/EP1223961A1/fr
Publication of EP1223961A4 publication Critical patent/EP1223961A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP00967122A 1999-09-30 2000-09-29 "trail" en tant qu'inhibiteur de l'inflammation auto-immune et de la progression du cycle cellulaire Withdrawn EP1223961A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15722299P 1999-09-30 1999-09-30
US157222P 1999-09-30
PCT/US2000/026862 WO2001022987A1 (fr) 1999-09-30 2000-09-29 'trail' en tant qu'inhibiteur de l'inflammation auto-immune et de la progression du cycle cellulaire

Publications (2)

Publication Number Publication Date
EP1223961A1 EP1223961A1 (fr) 2002-07-24
EP1223961A4 true EP1223961A4 (fr) 2005-10-05

Family

ID=22562828

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00967122A Withdrawn EP1223961A4 (fr) 1999-09-30 2000-09-29 "trail" en tant qu'inhibiteur de l'inflammation auto-immune et de la progression du cycle cellulaire

Country Status (5)

Country Link
EP (1) EP1223961A4 (fr)
JP (1) JP2003510288A (fr)
AU (1) AU766984B2 (fr)
CA (1) CA2386002A1 (fr)
WO (1) WO2001022987A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1501866A4 (fr) 2001-10-02 2006-02-08 Genentech Inc Variants de ligands apo-2 et leurs utilisations
EP1450847B1 (fr) 2001-11-13 2010-09-29 Genentech, Inc. Compositions à base de APO2 ligand/TRAIL et leur utilisation
EP1376134A1 (fr) * 2002-06-28 2004-01-02 Universitätsklinikum Charité Medizinische Fakultät der Humboldt-Universität zu Berlin Procédé de criblage d'inhibiteurs de TRAIL
JP2004149439A (ja) * 2002-10-30 2004-05-27 Katsuya Shiraki 移植拒絶免疫回避剤
WO2004087930A1 (fr) * 2003-03-28 2004-10-14 Saint Louis University Vecteurs competents pour la replication de l'adenovirus exprimant le trail (ligand induisant l'apoptose apparentee au facteur de necrose des tumeurs)
WO2005114187A2 (fr) * 2004-04-23 2005-12-01 The United States Of America As Represented By Thesecretary, Department Of Health And Human Services Procédés et compositions de diagnostic du sida et d’autres maladies et conditions impliquant l’activation du système immunitaire
ES2356880B8 (es) 2009-08-21 2012-10-30 Universidad De Zaragoza Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail.
WO2015138638A1 (fr) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Agonistes de récepteur de protéine trail à action prolongée pour le traitement de maladies auto-immunes
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EA201892260A1 (ru) 2016-04-07 2019-03-29 Дзе Джонс Хопкинс Юниверсити Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
US20250295730A1 (en) * 2022-06-03 2025-09-25 Mayo Foundation For Medical Education And Research METHODS AND MATERIALS FOR MODULATING T CELL ACTIVATION USING TRAILshort POLYPEPTIDES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766713A1 (fr) * 1997-08-04 1999-02-05 Bio Merieux Facteur proteique associe a une maladie neuro-degenerative et/ou auto-immune et/ou inflammatoire

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1666591T3 (da) * 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766713A1 (fr) * 1997-08-04 1999-02-05 Bio Merieux Facteur proteique associe a une maladie neuro-degenerative et/ou auto-immune et/ou inflammatoire

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GRIFFITH T S ET AL: "FUNCTIONAL ANALYSIS OF TRAIL RECEPTORS USING MONOCLONAL ANTIBODIES", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 162, no. 5, 1 March 1999 (1999-03-01), pages 2597 - 2605, XP000918935, ISSN: 0022-1767 *
HILLIARD ET AL: "Roles of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in experimental autoimmune encephalomyelitis", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 14, no. 6, April 2000 (2000-04-01), pages 1101, XP002953119, ISSN: 0892-6638 *
See also references of WO0122987A1 *
SONG K ET AL: "TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (TRAIL) IS AN INHIBITOR OF AUTOIMMUNE INFLAMMATION AND CELL CYCLE PROGRESSION", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 191, no. 7, 3 April 2000 (2000-04-03), pages 1095 - 1103, XP001164186, ISSN: 0022-1007 *

Also Published As

Publication number Publication date
AU766984B2 (en) 2003-10-30
EP1223961A1 (fr) 2002-07-24
CA2386002A1 (fr) 2001-04-05
AU7737100A (en) 2001-04-30
WO2001022987A1 (fr) 2001-04-05
JP2003510288A (ja) 2003-03-18

Similar Documents

Publication Publication Date Title
PT1027332E (pt) Novas lactamas inibidoras de metaloproteases
DE60142955D1 (de) Batterieladeverfahren und batterieblock
ID20640A (id) PROSES PEMBAKARAN NOx RENDAH
PT1049695E (pt) Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase
DE60043145D1 (de) Schadendetektion von Motorteilen
CY2014036I1 (el) Αλληλουχιες κυκλοϊου που συνδυαζονται με την ασθενεια της καχεξιας του χοιριδιου (map)
PT929528E (pt) Lactamas e imidas heterociclicas de aralquilo e de aralquilideno
NO990759D0 (no) Heterocykliske metallproteaseinhibitorer
DE69837782D1 (de) Batterieanordnung
EP1223961A4 (fr) "trail" en tant qu'inhibiteur de l'inflammation auto-immune et de la progression du cycle cellulaire
DE69801827D1 (de) Taktgenerator
DE60035990D1 (de) Mehrstufiger hybridgasgenerator von entspannungstyp
DE59800773D1 (de) Gasspeicher
FI974198A0 (fi) Generering av startvaerde
DE60030944D1 (de) Nummerierung von videobjekten und -zellen
DE69720520D1 (de) Taktgenerator
DE69905684T8 (de) Kraftstoffeinspritzvorrichtung der Accumulatorgattung
IS5932A (is) Amíðun peptíða með ensímum
DE69806750D1 (de) Amidinderivate als inhibitoren von no-synthase
ATE297084T1 (de) Synchronisierung von pcm und pseudozufallstaktgebern
DE59807433D1 (de) Brennkammer
DE69916223D1 (de) Redistribution von Silalkylene in ein Alkylreiche Silalkylen-enthaltende Rückstände
EP0998578A4 (fr) Sel-10 et utilisations de sel-10
FI970175L (fi) Oskillaattorin tehonkulutuksen minimointi
NO20001254D0 (no) Tennladningsblanding

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020430

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050823

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 38/16 A

Ipc: 7A 61K 38/17 B

Ipc: 7A 61P 37/00 B

Ipc: 7A 61K 48/00 B

17Q First examination report despatched

Effective date: 20061027

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071106